CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D005892: Gingivitis, Necrotizing Ulcerative NIH

(Synonyms: Gingivitis, Necrotizing Ulcerative)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1808 Photobiomodulation Wiki 1.00
drug2113 Routine Oral Care and Analgesia Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013280 Stomatitis NIH 1.00
D052016 Mucositis NIH 1.00
D006258 Head and Neck Neoplasms NIH 0.71
D014456 Ulcer NIH 0.41

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0010280 Stomatitis HPO 1.00
HP:0012288 Neoplasm of head and neck HPO 0.71

There is one clinical trial.

Clinical Trials


1 Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the incidence of severe oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving concurrent radiation and chemotherapy.

NCT03972527 Oral Mucositis (Ulcerative) Oral Mucositis (Ulcerative) Due to Radiation Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy Head and Neck Cancer Device: Photobiomodulation Other: Routine Oral Care and Analgesia
MeSH:Gingivitis, Necrotizing Ulcerative Head and Neck Neoplasms Mucositis Stomatitis Ulcer
HPO:Neoplasm of head and neck Stomatitis

Primary Outcomes

Description: The primary effectiveness endpoint of the study is the proportion of patients who have severe oral mucositis (Grade 3 or 4) at week 6 of treatment according to the World Health Organization (WHO) Oral Toxicity Scale.

Measure: Incidence of severe oral mucositis (WHO grade 3 and 4) at week 6 of chemoradiation therapy.

Time: 6-8 weeks of photobiomodulation and chemoradiation therapy

Secondary Outcomes

Description: Radiation therapy oncology group scale (RTOG) 0 (Normal)- 4 (necrosis/hemorrhage), 5= death

Measure: Oral Mucositis (OM) Grade and Incidence,

Time: 6-8 weeks, evaluated once per week

Description: World Health Organization scale (WHO) 0 (Normal)- 4 (oral alimentation not possible), 5= death

Measure: Oral Mucositis (OM) Grade and Incidence,

Time: 6-8 weeks, evaluated once per week

Description: World Health Organization (WHO) analgesic ladder Steps 1-3: 1= non opioid, 2= weak opioid, 3= strong opioid

Measure: Analgesic Usage

Time: 6-8 weeks, evaluated daily


HPO Nodes